BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  MacroGenics Shutters Phase II Cancer Study Following 7 Patient Deaths

  The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.

  July 11, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  HRA Pharma Seeks Approval for OTC Birth Control as Biden Mulls Emergency Action

  HRA Pharma, a Perrigo company, has submitted an application to the FDA seeking approval for the country’s first-ever over-the-counter (OTC) birth control pill.

  July 11, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  Roche Commits to IgAN Space with Another Asset from Long-time Partner Ionis

  The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.

  July 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Deals

  Vertex Buys ViaCyte in Synergistic Deal Aimed at Curing Type 1 Diabetes

  Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).

  July 11, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Exelixis to Approach FDA with Mixed Renal Cell Carcinoma Data

  Exelixis’ Cabometyx, in combination with two BMS-owned drugs, hit the primary endpoint of progression-free survival but missed the secondary endpoint of overall survival in renal cell carcinoma.

  July 11, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Worms: They’re a Lot Like Us, and that’s Good for Drug Development

  Roundworms are the cornerstone of scientific discoveries that have helped shape how we understand human disease and treatment. BioSpace takes a look at advances in C. elegans research.

  July 11, 2022

   · 

  5 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Long COVID Evidence Begins to Mount, Suggesting Biomarkers and a “Triangle” Effect

  Scientists found that SARS-CoV-2 spike protein in the plasma could be a hallmark of long COVID, suggesting that the virus can linger in the body who suffer from prolonged symptoms.

  July 11, 2022

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Employer Resources

  BLS Report Shows Steady Increase in Healthcare Employment & Wages

  The latest Employment Situation report from the Bureau of Labor Statistics shows that employment for healthcare workers is slowly but surely returning to its pre-pandemic levels.

  July 11, 2022

   · 

  2 min read

   · 

  Franklin Carpenter
• 

  Drug Development

  Tonix Anticipates Launch of Key Depression, Cocaine Intoxication Trials

  Tonix Pharmaceuticals announced a mid-stage study for major depressive disorder, which followed the June disclosure of a Phase II study for a cocaine intoxication therapy.

  July 11, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Drug Development

  Myrtelle Presents Latest Positive Data in Canavan Treatment Space

  Weeks after BridgeBio presented positive biomarker data in Canavan Disease, gene therapy company Myrtelle added its own data to the emerging research space.

  July 11, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN